NCT07398300Recruiting
Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion
Dynamic Whole-Body FDG and H₂¹⁵O PET-CT to Assess Insulin-Mediated Glucose Uptake and Organ Perfusion During GIP and GLP-1 Infusion in Healthy Individuals and Patients With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
This study investigates how the naturally occurring gut hormones GIP and GLP-1 influence whole-body glucose uptake and organ perfusion in humans. Using a state-of-the-art total-body PET-CT scanner, the study measures dynamic uptake of the glucose analogue 18F-FDG and blood flow using H₂¹⁵O across multiple organs during controlled elevations of plasma glucose and endogenous insulin secretion. The project consists of two sub-studies. Sub-study 1 includes healthy individuals who undergo three experimental visits with infusions of GIP, GLP-1, or saline (placebo) during a hyperglycemic clamp followed by FDG PET-CT scanning. Sub-study 2 includes healthy individuals and participants with type 2 diabetes who undergo two experimental visits with saline followed by either GIP or GLP-1 during a hyperglycemic clamp, combined with repeated H₂¹⁵O PET-CT measurements of perfusion. The primary aims are to quantify insulin-mediated skeletal muscle glucose uptake (sub-study 1) and skeletal muscle perfusion (sub-study 2). Secondary aims include assessment of glucose uptake and perfusion across adipose tissue, liver, and additional organs. The results will provide novel physiological insight into postprandial glucose metabolism and serve as reference data for future whole-body PET research.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 28 Jan 2026
- Start date
- 12 Mar 2026
- Primary completion date
- 12 Mar 2027
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Diseases
- Type 2 diabetes
- NCT number
- NCT07398300
What you commit to
- Study type: Interventional
- Planned participants: 36
- From 12 Mar 2026 to the primary completion date, 12 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous gastric or intestinal resection (except appendectomy or cholecystectomy) or major abdominal surgery (including bariatric surgery)
- Initiation of special diets, major lifestyle changes, or weight loss \> 5% within 3 months prior to or during the study
Other illness
- Chronic obstructive pulmonary disease (Sub-study 2 only)
- Any medication or physical/psychological condition that may interfere with participation (per investigator judgement)
Lab values
- Anaemia (haemoglobin below normal range)
- ALT \> 2× upper normal limit or any known hepatobiliary or gastrointestinal disorder
- Kidney disease (creatinine above normal range)
- For Sub-study 1: Type 1 or type 2 diabetes or HbA1c ≥ 42 mmol/mol
- Use of glucose-lowering medications other than metformin (Sub-study 2 only)
Other
- Regular tobacco smoking or use of nicotine-containing products
- Claustrophobia
- Pregnancy, breastfeeding, or intention to become pregnant during the study period
- Inability to speak or read Danish
Criteria the registry did not label
- Sub-study 1 (Healthy individuals):
- Age 23-50 years
- BMI 20.0-26.9 kg/m²
- HbA1c \< 42 mmol/mol
- Able to provide informed consent
- Sub-study 2 - Participants with Type 2 Diabetes:
- Age 23-60 years
- Diagnosed with type 2 diabetes for ≥3 months
- HbA1c \> 53 mmol/mol
- Treatment with metformin only
- Able to provide informed consent
- Sub-study 2 - Healthy control participants:
- Age 23-64 years
- HbA1c \< 42 mmol/mol
- Able to provide informed consent
Age in the registry: 23 years to 64 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Copenhagen University Hospital, Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.